Sleep Disorder Market Size - By Disorder Type, By Product, By End Use, Growth Forecast, 2026 - 2035

Sleep Disorder Market Size

The global sleep disorder market was valued at USD 30.5 billion in 2025. The market is expected to reach from USD 33.8 billion in 2026 to USD 78.6 billion in 2035, growing at a CAGR of 9.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

The high market growth is attributed to the rising prevalence of sleep disorders, increasing awareness and diagnosis rates, and technological advancements in sleep diagnostics and therapies, among other contributing factors.
 

Sleep disorder are medical conditions that impact the quality, timing, and duration of sleep, resulting in poor daily performance and general health. These disorders include insomnia, sleep apnea, narcolepsy, restless legs syndrome, and circadian rhythm abnormalities, which can be caused by physiological, psychological, or behavioural causes.
 

The major players in the global sleep disorder market are ResMed, PHILIPS, Fisher & Paykel Healthcare, BMC Medical, and Drive Devilbiss. These companies maintain their competitive position through ongoing product innovation, global market presence, and substantial investment in research and development.
 

The market has increased from USD 22.5 billion in 2022 and reached USD 27.4 billion in 2024, with the historic growth rate of 11%. The market growth was driven by expanding geriatric populations, increasing burden of obesity and cardiometabolic diseases, improved reimbursement coverage for sleep diagnostics, and the shift toward home-based sleep testing and treatment solutions.
 

Moreover, rising cases of insomnia, obstructive sleep apnea, restless leg syndrome, and circadian rhythm disorders are fuelling demand. For instance, according to the Centers for Disease Control and Prevention (CDC), around 35% of adults in the U.S. reported insufficient sleep in 2022, with this trend expected to persist through 2025. Key contributors include sedentary lifestyles, increased screen time, stress, and irregular work hours.
 

In addition, the International Telecommunication Union (ITU) reported that global internet usage reached 66% in 2022, reflecting heightened screen time, which is a significant factor impacting sleep patterns. Urbanization and changing sleep habits are also expanding the global patient demographic, as the World Bank projected that urban populations would grow by 1.84% annually between 2022 and 2025.
 

Furthermore, innovation in polysomnography systems, wearable sleep trackers, CPAP devices, and AI-enabled diagnostics enhances treatment accuracy and patient compliance. Compact, home-use, and connected devices are gaining strong adoption. These advances reduce barriers to long-term therapy usage.

Sleep Disorder Market Trends

The sleep disorder industry is growing considerably with the shift toward home-based diagnosis and treatment, integration of digital health and AI technologies, rising adoption of wearables and consumer sleep trackers, and focus on patient-centric and personalized therapies, among other factors collectively driving the industry growth.
 

• Patients are increasingly choosing home sleep testing over in-lab polysomnography due to reduced costs and more convenience. Remote monitoring is possible with portable diagnostic instruments and CPAP systems that are connected. Tele-sleep services facilitate follow-ups and therapeutic optimization, increasing access to underserved areas.
   
• Smartwatches, rings, and bedside sensors are gaining popularity for continuous sleep monitoring. These devices increase consumer engagement and awareness of sleep health. Data generated from wearables is increasingly integrated into clinical decision-making.
   
• Sleep health is increasingly recognized as a pillar of preventive medicine and workplace wellness. Employers and insurers promote screening programs to reduce long-term health risks. Early intervention strategies support sustained market growth.
   
• Further, manufacturers are developing customized CPAP masks, pressure settings, and digital coaching tools to improve comfort. Behavioral therapy apps and personalized sleep programs are expanding. Improved patient experience helps reduce therapy discontinuation rates, thereby sustaining market growth.
   

Sleep Disorder Market Analysis

The market was valued at USD 22.5 billion in 2022. The market size reached USD 27.4 billion in 2024, from USD 24.9 billion in 2023.
 

Based on disorder type, the sleep disorder market is segmented into sleep apnea, insomnia, restless legs syndrome (RLS), narcolepsy, and other disorder types. The sleep apnea segment has asserted its dominance in the market by securing a significant market share of 48.2% in 2025 owing to its high prevalence among ageing and obese populations, strong clinical awareness, and widespread adoption of CPAP and home-based diagnostic solutions. The segment is expected to exceed USD 39.5 billion by 2035, growing at a CAGR of 10.3% during the forecast period.
 

On the other hand, the narcolepsy segment is expected to grow with a CAGR of 8.9%. Improved diagnostic rates, increased awareness among healthcare professionals, and the introduction of novel therapies targeting excessive daytime sleepiness are all driving this segment's growth.
 

• The sleep apnea segment continues to lead the market. Obesity is a major risk factor for obstructive sleep apnea, and its global prevalence is rising. Increased fat deposition in the neck and upper airway increases the risk of airway collapse during sleep. Diabetes and metabolic syndrome are becoming more common, increasing the risk of sleep apnea. This growing at-risk population immediately raises the demand for diagnostic and therapeutic options.
   
• Sleep apnea prevalence increases with age due to reduced muscle tone and anatomical abnormalities in the airway. Comorbid diseases such as cardiovascular disease and hypertension are common in older people and are closely linked to sleep apnea. Doctors are increasingly screening the elderly as part of their chronic illness treatment. This promotes long-term growth in sleep apnea tests and treatments.
   
• The insomnia segment held a revenue of USD 6.8 billion in 2025, with projections indicating a steady expansion at 9.6% CAGR from 2026 to 2035. Rising stress levels, mental health disorders, and increased screen time associated with modern lifestyles all contribute to increased sleep disruption in this segment. Increasing acceptance of behavioral therapies, digital CBT-I platforms, and prescription sleep aids contributes to segment growth.
   
• The restless legs syndrome (RLS) segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 10% over the forecast period. The segment is driven by an increase in the prevalence of iron deficiency, chronic kidney disease, and neurological disorders, all of which increase the risk of RLS. Furthermore, growing awareness of symptom management and the availability of pharmacological and non-pharmacological treatments are driving market growth.
   

Based on product, the sleep disorder market is segmented into therapeutics and diagnostics. The therapeutics segment dominated the market in 2025, accounting for USD 19.2 billion and is anticipated to grow at a CAGR of 10.2% during the forecast period.
 

• The growing prevalence of insomnia, sleep apnea, and circadian rhythm disorders is driving demand for therapeutic interventions. The growing awareness of the negative impact of untreated sleep disorders on health is driving up adoption of medications and device-based therapies.
   
• CPAP, BiPAP, oral appliances, and neurostimulation devices are being used more frequently to treat sleep disorders, particularly sleep apnea. Device innovation, comfort enhancements, and connectivity features all contribute to increased patient compliance.
   
• The diagnostics segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 9.1% over the forecast period. Growth in this segment is being driven by a number of factors, including the growing need for early detection of sleep disorders, the increased use of sophisticated polysomnography and home sleep apnea testing devices, and the integration of AI and cloud-based analytics for precise and effective diagnosis.
  
  

Based on end use, the sleep disorder market is classified into home care settings & individuals and sleep laboratories & hospitals. The home care settings & individuals segment dominated the market with a revenue share of 58.5% in 2025 and is expected to reach USD 46.9 billion within the forecast period.
 

• Patients increasingly prefer managing sleep disorders at home to avoid the inconvenience and discomfort of in-lab sleep studies. Portable diagnostic devices and home-use CPAP systems make monitoring and therapy easier. This trend improves patient compliance and engagement.
   
• Home-use sleep diagnostic tools, smart sleep trackers, and connected CPAP devices allow continuous monitoring and real-time feedback. Integration with apps and cloud platforms enables patients and caregivers to track progress conveniently. Technology reduces dependence on hospital visits.
   
• The sleep laboratories & hospitals segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 9.5% over the forecast period. Rising referrals for complicated sleep disorder patients, increased investments in specialist sleep centers, and the expanding use of in-lab polysomnography for accurate diagnosis and treatment planning are driving the segment's growth.
   

North America Sleep Disorder Market

North America dominated the sleep disorder industry with the highest market share of 38.1% in 2025.
 

• The U.S. sleep disorder industry was valued at USD 8.1 billion and USD 8.9 billion in 2022 and 2023, respectively. The market size reached USD 10.7 billion in 2025, growing from USD 9.7 billion in 2024, and is anticipated to grow at a CAGR of 8.7% between 2026 to 2035.
   
• North America has a well-established healthcare system that provides easy access to specialized sleep clinics, diagnostic facilities, and modern medications. Modern polysomnography and home sleep testing devices are available in hospitals and outpatient centers. The infrastructure enables speedier adoption and increased treatment penetration.
   
• Moreover, healthcare providers and patients are increasingly aware of the link between sleep disorders and conditions like cardiovascular diseases, diabetes, and depression. Screening for sleep disorders has become routine in preventive healthcare, boosting market growth.
   

Europe Sleep Disorder Market

Europe sleep disorder industry accounted for USD 9 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• European countries such as Germany, Italy, and the UK have a rapidly aging population prone to sleep disturbances. Age-related comorbidities, including hypertension, neurodegenerative diseases, and metabolic disorders, increase the need for effective sleep disorder management solutions.
   
• National health programs actively promote sleep health awareness, funding sleep clinics and research programs. EU-level initiatives also support the adoption of advanced diagnostic tools and therapeutics, increasing market uptake.
   
• Additionally, strong healthcare budgets in Western Europe allow hospitals and private clinics to adopt advanced diagnostic and therapeutic devices. Investments in digital health solutions further enhance patient monitoring and adherence.
   

Asia Pacific Sleep Disorder Market

The Asia Pacific sleep disorder industry is anticipated to grow at the highest CAGR of 11.3% during the analysis timeframe.
 

• Rapid urbanization extended working hours, increased screen time, and high-stress lifestyles contribute to a surge in sleep disorders. These factors significantly increase demand for both pharmacological treatments and device-based therapies in urban populations.
   
• Awareness campaigns by healthcare providers, NGOs, and telemedicine platforms highlight the health risks of untreated sleep disorders. Public understanding of sleep apnea, insomnia, and circadian disorders is driving early diagnosis and intervention.
   
• Moreover, home sleep monitoring devices, mobile apps, and connected CPAP machines are increasingly being adopted in APAC markets. Tech-savvy populations prefer data-driven therapy management and telemedicine consultations.
   

Latin America Sleep Disorder Market

The Latin America sleep disorder industry is experiencing robust growth over the analysis timeframe.
 

• The shortage of specialized sleep labs in many regions has accelerated adoption of home sleep testing and portable therapy devices. Home care solutions are becoming the preferred choice due to convenience and affordability.
   
• Healthcare providers are increasingly trained to recognize and manage sleep disorders, particularly obstructive sleep apnea. Patient education campaigns are enhancing early diagnosis and treatment adoption.
   
• Moreover, emerging government programs in Brazil, Argentina, and Chile support access to diagnostic tests and CPAP devices. Increasing insurance penetration encourages patients to seek treatment without financial barriers.
   

Middle East & Africa Sleep Disorder Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.
 

• Countries such as Saudi Arabia, UAE, and South Africa have high obesity and diabetes rates, contributing significantly to sleep apnea and other sleep disorders. Lifestyle changes and dietary patterns exacerbate the problem, driving therapy demand.
   
• Further, private hospitals and expanding insurance coverage in Gulf countries support access to advanced diagnostics and therapeutics. Patients are increasingly willing to invest in modern sleep disorder solutions.
   

Sleep Disorder Market Share

The sleep disorder industry is competitive, driven by a mix of established medical device manufacturers and emerging sleep-tech companies. Leading players focus on expanding their product portfolios across diagnostics, therapeutic devices, and home-based solutions, while investing heavily in R&D for innovative and patient-friendly technologies. Strategic partnerships, mergers, and acquisitions are also common as companies aim to strengthen their regional presence and enhance capabilities in AI-enabled diagnostics and digital sleep monitoring.
 

Key players include ResMed, PHILIPS, Fisher & Paykel Healthcare, BMC Medical, and Drive Devilbiss, collectively accounting for ~67% of the total market share. These companies dominate through advanced CPAP/BiPAP devices, sleep diagnostic systems, and connected digital platforms, benefiting from strong brand recognition and established global distribution networks. Smaller and emerging players are focusing on niche segments, such as wearable sleep trackers and home-based sleep therapies, to differentiate themselves and capture untapped market opportunities.
 

The competitive landscape is expected to evolve further with increased adoption of telemedicine, AI-driven solutions, and personalized therapies, enabling both incumbents and new entrants to address the growing demand for effective sleep disorder management across clinical and consumer segments.
 

Sleep Disorder Market Companies

A few of the prominent players operating in the sleep disorder industry include:

• Apple
• BMC Medical
• Cadwell
• Drive Devilbiss
• Fisher & Paykel Healthcare
• Natus
• Nihon Kohden
• Oura Health
• PHILIPS
• ResMed
• Sleep Shepherd
• Sleepace
• WEINMANN Medical
• WITHINGS
• ZOLL Medical
   

ResMed ResMed’s comprehensive portfolio of CPAP, BiPAP, and ventilatory devices, coupled with a robust digital health ecosystem for remote monitoring and patient adherence. Its strong global presence and continuous innovation in cloud-connected therapy solutions further enhance its market leadership.
 

PHILIPS It stands out for its integrated sleep diagnostics and therapy offerings, combining in-lab and home-based solutions with advanced connected platforms. Its global distribution network and strong clinical partnerships strengthen accessibility and adoption of its sleep care technologies.
 

Fisher & Paykel Healthcare Fisher & Paykel Healthcare focus on patient comfort through innovative CPAP devices and humidification systems, improving compliance and therapy outcomes. The company’s commitment to ergonomic, user-friendly designs and home-based solutions drives its appeal in the market.
 

Sleep Disorder Industry News:

• In January 2026, Inogen, Inc. announced the launch of Aurora CPAP masks, adding a new product to its respiratory care portfolio. Aurora’s introduction marked a strategic milestone in expanding Inogen’s presence in obstructive sleep apnea (OSA) care. This launch is expected to strengthen the market by increasing patient access to high-quality CPAP masks and driving adoption of advanced therapeutic devices.
   
• In December 2025, ResMed announced that it had received U.S. FDA clearance for Personalized Therapy Comfort Settings (PTCS), marketed as Smart Comfort. It became the first FDA-cleared AI-enabled device to recommend personalized comfort settings for CPAP users with obstructive sleep apnea (OSA). This innovation is anticipated to support the market by enhancing therapy adherence, improving patient outcomes, and encouraging wider adoption of AI-driven sleep solutions.
   

The sleep disorder market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Market, By Disorder Type

• Sleep apnea
  • Obstructive sleep apnea
  • Central sleep apnea
  • Complex sleep apnea
• Insomnia
• Restless legs syndrome (RLS)
• Narcolepsy
• Other disorder types
   

Market, By Product

• Therapeutics
  • Therapeutic devices
    • Positive airway pressure (PAP) devices
      • Continuous positive airway pressure (CPAP) devices
      • Bilevel positive airway pressure (BiPAP) devices
      • Automatic positive airway pressure (APAP) devices
    • Oral appliances
      • Mandibular advancement devices
      • Tongue-retaining devices
      • Rapid maxillary expansion
      • Mouth guards
    • Adaptive servo-ventilation (ASV)
    • Airway clearance system
    • Oxygen devices
    • Other therapeutic devices
  • Cognitive behavioral therapy
• Diagnostics
  • Polysomnography (PSG) device
    • Ambulatory PSG devices
    • Clinical PSG devices
  • Home sleep testing (HST) devices
    • Type 2
    • Type 3
    • Type 4
  • Actigraphy systems
  • Sleep screening devices
  • Pulse oximeter
  • Respiratory polygraph
  • Wearables
    • Smart watches & bands
    • Other wearables
       

Market, By End Use

• Home care settings & individuals
• Sleep laboratories & hospitals
   

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE